This page is an automatically generated summary of information from the Federal Court, Federal Court of Appeal, Health Canada and other websites. This information should NOT be relied upon as it is automatically generated and has not been confirmed for accuracy.

Automatically generated on April 18, 2025.

Return to the list of Patented Medicine Litigation page.

---

---

Rivaroxaban

PMSCRIVAROXABAN, XARELTO – PHARMASCIENCE INC (NOC Search)

Patents:

• 2396561: SANDOZ, APOTEX, PHARMASCIENCE, TEVA, MINT, REDDY, TEVA, TARO PHARMACEUTICALS, SANDOZ, APOTEX
• 2451258: REDDY, TEVA
• 2547113: APOTEX, JAMP, SANDOZ, APOTEX, TARO PHARMACEUTICALS, TEVA, ACCORD HEALTHCARE, PHARMASCIENCE, TEVA, TARO PHARMACEUTICALS, APOTEX, SANDOZ, MINT, TARO PHARMACEUTICALS, SANDOZ, TEVA, REDDY, TEVA, TARO PHARMACEUTICALS, SANDOZ, APOTEX
• 2624310: MINT, TEVA, TARO PHARMACEUTICALS, APOTEX, SANDOZ, TARO PHARMACEUTICALS, SANDOZ, APOTEX, TARO PHARMACEUTICALS, TEVA, APOTEX, JAMP, ACCORD HEALTHCARE, PHARMASCIENCE, REDDY, TEVA, TARO PHARMACEUTICALS, SANDOZ, APOTEX, SANDOZ, TEVA
• 2634310: TEVA
• 2823159: JAMP, APOTEX, SANDOZ, APOTEX, TARO PHARMACEUTICALS, TEVA, ACCORD HEALTHCARE, PHARMASCIENCE, MINT, TEVA, TARO PHARMACEUTICALS, APOTEX, SANDOZ, TARO PHARMACEUTICALS, SANDOZ, TEVA, REDDY, TEVA, TARO PHARMACEUTICALS, SANDOZ, APOTEX
• 2993858: REDDY
• 9415053: TEVA, TARO PHARMACEUTICALS, APOTEX, SANDOZ

ACCORD HEALTHCARE

• PM(NOC) – T-1221-19

APOTEX

• PM(NOC) – T-2093-18 (2020 FC 325, 2020 FC 866)
• Other – 20-A-34

JAMP

• PM(NOC) – T-591-20

MINT

• PM(NOC) – T-605-20

PHARMASCIENCE

• PM(NOC) – T-270-20

REDDY

• PM(NOC) – T-1187-19 (2019 FC 1408)
• Infringement – T-1029-21

SANDOZ

• PM(NOC) – T-806-19

SANDOZ, APOTEX, TARO PHARMACEUTICALS, TEVA

• Other – 19-A-65

TARO PHARMACEUTICALS

• PM(NOC) – T-435-19

TEVA

• PM(NOC) – T-1021-19 – T-1960-18 (2019 FC 191, 2019 FC 1039, 2019 FC 1370)

TEVA, TARO PHARMACEUTICALS, APOTEX, SANDOZ

• Appeal – A-15-20 (2020 FCA 72) – A-16-20 (2020 FCA 71)

TEVA, TARO PHARMACEUTICALS, SANDOZ, APOTEX

• PM(NOC) – A-388-19 (2020 FCA 86)

---

Return to the Patented Medicine Litigation page.